• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Angiotensin II vaccine: a novel approach in the treatment of hypertension.
【24h】

Angiotensin II vaccine: a novel approach in the treatment of hypertension.

机译：血管紧张素II疫苗：一种治疗高血压的新方法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Hypertension affects approximately 65 million Americans, resulting in 30 million office visits per year. Only about one third of patients have blood pressure below goal. Poor adherence to drug therapy is an important contributor to this statistic. An active immunization, which would induce antibodies against angiotensin, could simplify and improve treatment. An ideal regimen would be a few subcutaneous injections per year, which in turn could vastly improve adherence and subsequent outcomes. OBJECTIVE: To discuss Cyt006-AngAb, a novel vaccine targeting angiotensin II, which is chemically linked to recombinant virus-like particles. Emphasis is placed on current progress of this vaccine's clinical trials. METHODS: Relevant literature is discussed. CONCLUSION: Although advances in hypertension vaccines have faced challenges, the angiotensin II vaccine may provide a promising approach in the control of hypertension.
机译：背景：高血压影响约6500万美国人，每年导致3000万人次就诊。只有约三分之一的患者血压低于目标。对药物治疗的依从性差是造成这一统计数字的重要原因。主动免疫可以诱导抗血管紧张素抗体，可以简化和改善治疗方法。理想的治疗方案是每年皮下注射几次，这反过来可以大大改善依从性和后续结果。目的：探讨Cyt006-AngAb，这是一种靶向血管紧张素II的新型疫苗，该疫苗化学连接至重组病毒样颗粒。重点放在该疫苗临床试验的最新进展上。方法：讨论相关文献。结论：尽管高血压疫苗的发展面临挑战，但血管紧张素II疫苗可能为控制高血压提供了有希望的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号